Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial

This open‐label multicenter phase 1 study evaluated the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of weekly carfilzomib and dexamethasone (Cd) in Japanese patients with relapsed or refractory multiple myeloma (RRMM). Carfilzomib was administered by 30‐minute intravenous i...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Dai, Tobinai, Kensei, Chou, Takaaki, Taniwaki, Masafumi, Shumiya, Yoshihisa, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172054/
https://www.ncbi.nlm.nih.gov/pubmed/30058108
http://dx.doi.org/10.1111/cas.13753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172054/
https://www.ncbi.nlm.nih.gov/pubmed/30058108
http://dx.doi.org/10.1111/cas.13753

Ejemplares similares